Studies indicate that early cancer detection can significantly reduce mortality. For example, ovarian cancer is the leading cause of death from gynecologic cancers in the United States and the fifth-leading cause of cancer death in women. An estimated 22,000 new cases occur annually in the United States. The disease is difficult to detect early because it typically triggers few noticeable symptoms. By the time ovarian cancer is detected, it is often too advanced and difficult to control. Research has shown that the five-year survival rate for women diagnosed in the later stages of the disease is as low as 20 to 30 percent. However, the survival rate can be greater than 90 percent when ovarian cancer is detected in its early stages.
Fujirebio Diagnostics developed an HE4 test to be used in conjunction with the company's existing CA125 biomarker, the current gold standard for monitoring ovarian cancer. This combination of biomarkers, as published clinical data shows, provides clinicians with a diagnostic tool that can provide higher sensitivity and specificity than CA125 alone. Improved sensitivity and specificity should allow clinicians to distinguish between benign and malignant pelvic masses more accurately, helping to ensure that patients receive appropriate therapy earlier.
About Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is one of the group companies of Miraca Holdings, Inc., in Japan,
|SOURCE BD-Becton Dickinson|
Copyright©2009 PR Newswire.
All rights reserved